NasdaqCM - Delayed Quote USD

MyMD Pharmaceuticals, Inc. (MYMD)

2.8100 -0.0500 (-1.75%)
At close: April 25 at 4:00 PM EDT
2.8600 +0.05 (+1.78%)
After hours: April 25 at 5:51 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Christopher C. Chapman Jr., M.D. President, Chief Medical Officer & Director 665.76k -- 1953
Mr. Ian Rhodes CPA Interim Chief Financial Officer 162k -- 1973

MyMD Pharmaceuticals, Inc.

855 North Wolfe Street
Suite 601
Baltimore, MD 21205
United States
856 848 8698 https://www.mymd.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
6

Description

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

Corporate Governance

MyMD Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Mar 29, 2024 - Apr 02, 2024
MyMD Pharmaceuticals, Inc. Earnings Call

Related Tickers

PXMD PaxMedica, Inc.
0.7042
+1.76%
 
RLYB Rallybio Corporation
1.6500
+4.43%
 
DRMA Dermata Therapeutics, Inc.
0.3401
-3.27%
 
ADIL Adial Pharmaceuticals, Inc.
1.7300
+1.17%
 
ADXN Addex Therapeutics Ltd
15.41
-0.90%
 
ATNF 180 Life Sciences Corp.
1.7688
-2.81%
 
XLO Xilio Therapeutics, Inc.
1.0100
-4.72%
 
VRPX Virpax Pharmaceuticals, Inc.
2.9184
-5.55%
 
LGVN Longeveron Inc.
1.6700
-2.91%
 
BLPH Bellerophon Therapeutics, Inc.
0.0550
+1.66%